Targeted Therapy in Melanoma – Richard D Carvajal MD

Richard D. Carvajal, MD, Director of the Experimental Therapeutics/Phase I program and Melanoma at Columbia University describes the future of targeted therapy – BRAF, MEK, and others in relation to clinical trials for metastatic melanoma at The Angeles Clinic Melanoma Education Symposium 2015 – www.theangelesclinic.org